Millennium Management’s Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant IBER.U Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q4
Sell
-134,735
Closed -$1.35M 7625
2021
Q3
$1.35M Sell
134,735
-195,383
-59% -$1.95M ﹤0.01% 4357
2021
Q2
$3.32M Sell
330,118
-194,882
-37% -$1.95M ﹤0.01% 3318
2021
Q1
$5.18M Buy
+525,000
New +$5.25M ﹤0.01% 2533

Other funds holding IBER.U

Millennium Management's IBER.U Position: Q4 2021 in Review

Millennium Management sold out of Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant (IBER.U) in Q4 2021, closing a stake of 134,735 shares — an estimated $1.35M sold.

Millennium Management first reported a position in IBER.U in Q1 2021 and held it in 3 quarters. The position peaked at $5.18M in Q1 2021. 23 funds tracked by Wall St. Rank hold IBER.U as of Q4 2021.

  • Millennium Management reported no remaining Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant position as of Q4 2021 after selling out during the quarter.
  • Millennium Management sold 134,735 Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant shares in Q4 2021, an estimated $1.35M.
  • Millennium Management first reported a position in Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant in Q1 2021 and held it in 3 quarters.
  • Millennium Management's Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant position peaked at $5.18M in Q1 2021.
  • 23 funds tracked by Wall St. Rank held Ibere Pharmaceuticals Units, each consisting of one Class A ordinary share and one-half of one Redeemable Warrant as of Q4 2021.

Based on Millennium Management's 13F filing for Q4 2021, filed 14 Feb 2022.